Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Bastian

Showing results (71-80 of 94) with videos related to

Pageof 10
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|November 27, 2025
Comparison of mCRPC [<sup>177</sup>Lu]Lu-PSMA-617 radioligand therapy with and without concurrent enzalutamide medication in a real-world settingFlorian Rosar, Fadi Khreish, Caroline Burgard, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 6, 2026
Zirconium-89-based PSMA PET/CT with delayed imaging for early detection of biochemical recurrence in prostate cancer patients with PSA ≤ 0.2 ng/mL: A feasibility studyTilman Speicher, Simon Latell, Arne Blickle, et al.
Nuklearmedizin. Nuclear Medicine|May 20, 2025
Correction: Digitalization of Nuclear Medicine in Germany - Status Quo 2024Thomas Wendler, Julian Manuel Michael Rogasch, Moritz B Bastian, et al.
Cancers|October 26, 2024
Analysis of Molecular Imaging Biomarkers Derived from [<sup>18</sup>F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis (TLG) Predicts Overall Survival in Patients Undergoing [<sup>225</sup>Ac]Ac-PSMA-617-Augmented [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand TherapyCaroline Burgard, Fadi Khreish, Lukas Dahlmanns, et al.
Nuklearmedizin. Nuclear Medicine|April 17, 2025
Digitalization of Nuclear Medicine in Germany - Status Quo 2024Thomas Wendler, Julian Manuel Michael Rogasch, Moritz B Bastian, et al.
Clinical Nuclear Medicine|May 4, 2026
Outcome and Safety of Radioligand Therapy With [161Tb]Tb-PSMA-617 After Re-Progression in mCRPC Patients Previously Treated With [177Lu]Lu-PSMA-617Florian Rosar, Caroline Burgard, Sophia Phuong Thao Hoang, et al.
Cardiovascular and Interventional Radiology|November 4, 2020
Digital Variance Angiography in Lower-Limb Angiography with Metal ImplantsM B Bastian, A M König, S Viniol, et al.
Clinical Nuclear Medicine|January 9, 2025
225 Ac-PSMA-617 Augmentation After Insufficient Response Under 177 Lu-PSMA-617 Radioligand Therapy in mCRPC: Evaluation of Outcome and Safety From a Prospective Registry (REALITY Study)Florian Rosar, Fadi Khreish, Lea Sophie Nagel, et al.
Physical Review Letters|June 21, 2024
Observation of Interatomic Coulombic Decay Induced by Double Excitation of Helium in NanodropletsB Bastian, J D Asmussen, L Ben Ltaief, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 7, 2026
Real-world evaluation of [<sup>177</sup>Lu]Lu-PSMA-617 RLT in post-taxane mCRPC: feasibility and safety of individualized treatment in a challenging cohortMuammer Misirci, Florian Rosar, Fadi Khreish, et al.
Pageof 10

Showing results (71-80 of 94) with videos related to

Sort By:
Pageof 10
European Journal of Nuclear Medicine and Molecular Imaging|November 27, 2025
Comparison of mCRPC [<sup>177</sup>Lu]Lu-PSMA-617 radioligand therapy with and without concurrent enzalutamide medication in a real-world settingFlorian Rosar, Fadi Khreish, Caroline Burgard, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 6, 2026
Zirconium-89-based PSMA PET/CT with delayed imaging for early detection of biochemical recurrence in prostate cancer patients with PSA ≤ 0.2 ng/mL: A feasibility studyTilman Speicher, Simon Latell, Arne Blickle, et al.
Nuklearmedizin. Nuclear Medicine|May 20, 2025
Correction: Digitalization of Nuclear Medicine in Germany - Status Quo 2024Thomas Wendler, Julian Manuel Michael Rogasch, Moritz B Bastian, et al.
Cancers|October 26, 2024
Analysis of Molecular Imaging Biomarkers Derived from [<sup>18</sup>F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis (TLG) Predicts Overall Survival in Patients Undergoing [<sup>225</sup>Ac]Ac-PSMA-617-Augmented [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand TherapyCaroline Burgard, Fadi Khreish, Lukas Dahlmanns, et al.
Nuklearmedizin. Nuclear Medicine|April 17, 2025
Digitalization of Nuclear Medicine in Germany - Status Quo 2024Thomas Wendler, Julian Manuel Michael Rogasch, Moritz B Bastian, et al.
Clinical Nuclear Medicine|May 4, 2026
Outcome and Safety of Radioligand Therapy With [161Tb]Tb-PSMA-617 After Re-Progression in mCRPC Patients Previously Treated With [177Lu]Lu-PSMA-617Florian Rosar, Caroline Burgard, Sophia Phuong Thao Hoang, et al.
Cardiovascular and Interventional Radiology|November 4, 2020
Digital Variance Angiography in Lower-Limb Angiography with Metal ImplantsM B Bastian, A M König, S Viniol, et al.
Clinical Nuclear Medicine|January 9, 2025
225 Ac-PSMA-617 Augmentation After Insufficient Response Under 177 Lu-PSMA-617 Radioligand Therapy in mCRPC: Evaluation of Outcome and Safety From a Prospective Registry (REALITY Study)Florian Rosar, Fadi Khreish, Lea Sophie Nagel, et al.
Physical Review Letters|June 21, 2024
Observation of Interatomic Coulombic Decay Induced by Double Excitation of Helium in NanodropletsB Bastian, J D Asmussen, L Ben Ltaief, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 7, 2026
Real-world evaluation of [<sup>177</sup>Lu]Lu-PSMA-617 RLT in post-taxane mCRPC: feasibility and safety of individualized treatment in a challenging cohortMuammer Misirci, Florian Rosar, Fadi Khreish, et al.
Pageof 10